AP1891A - HIV immunogenic compositions and methods. - Google Patents

HIV immunogenic compositions and methods.

Info

Publication number
AP1891A
AP1891A APAP/P/2001/002300A AP2001002300A AP1891A AP 1891 A AP1891 A AP 1891A AP 2001002300 A AP2001002300 A AP 2001002300A AP 1891 A AP1891 A AP 1891A
Authority
AP
ARIPO
Prior art keywords
mammal
immunogenic compositions
hiv
iss
adjuvant
Prior art date
Application number
APAP/P/2001/002300A
Other versions
AP2001002300A0 (en
Inventor
Ronald B Moss
Original Assignee
The Immune Response Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Immune Response Corp filed Critical The Immune Response Corp
Publication of AP2001002300A0 publication Critical patent/AP2001002300A0/en
Application granted granted Critical
Publication of AP1891A publication Critical patent/AP1891A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides immunogenic compositions which enhance ?-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing b-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting aids, by enhancing ?-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
APAP/P/2001/002300A 1999-05-06 2000-05-05 HIV immunogenic compositions and methods. AP1891A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US15066799P 1999-08-25 1999-08-25
PCT/US2000/012495 WO2000067787A2 (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods

Publications (2)

Publication Number Publication Date
AP2001002300A0 AP2001002300A0 (en) 2001-12-31
AP1891A true AP1891A (en) 2008-09-23

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002300A AP1891A (en) 1999-05-06 2000-05-05 HIV immunogenic compositions and methods.

Country Status (8)

Country Link
EP (1) EP1176978A2 (en)
AP (1) AP1891A (en)
AU (1) AU4992900A (en)
BR (1) BR0010323A (en)
CA (1) CA2372960C (en)
CR (1) CR6491A (en)
OA (1) OA11937A (en)
WO (1) WO2000067787A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (en) 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
ATE306938T1 (en) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa USE OF CPG AS AN ADJUVANT FOR HIV VACCINE
CA2430691A1 (en) 2000-12-27 2002-07-04 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US20030044428A1 (en) * 2001-01-26 2003-03-06 Moss Ronald B. Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
US20030199466A1 (en) 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DE60229422D1 (en) 2001-08-17 2008-11-27 Coley Pharm Gmbh COMBINATION MOTIF IMMUNOSTIMULATING OLIGONUCLEOTIDES WITH IMPROVED EFFECT
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP1551221A4 (en) * 2002-07-03 2007-08-01 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
EA008777B1 (en) 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004058179A2 (en) 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
AU2004269379A1 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic HIV compositions and related methods
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
EP3424495A1 (en) 2011-07-06 2019-01-09 GlaxoSmithKline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5087758B2 (en) * 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Vaccine, GB, Butterworth Scientific, Guildford, Vol. 16, No. 7, 1 *
Vaccine, Vol. 18, No. 11-12, 01/2000 *

Also Published As

Publication number Publication date
WO2000067787A2 (en) 2000-11-16
CA2372960C (en) 2006-03-28
BR0010323A (en) 2002-01-08
WO2000067787A3 (en) 2001-04-26
AP2001002300A0 (en) 2001-12-31
CA2372960A1 (en) 2000-11-16
EP1176978A2 (en) 2002-02-06
CR6491A (en) 2005-05-31
OA11937A (en) 2006-04-12
AU4992900A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
AP1891A (en) HIV immunogenic compositions and methods.
MXPA01011047A (en) Neisseria genomic sequences and methods of their use.
MY129263A (en) Vaccine composition
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
TW200621806A (en) Vaccine
EP1373301A4 (en) Reducing the immunogenicity of fusion proteins
WO2001053463A3 (en) COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
MXPA01003557A (en) Neisseria genomic sequences and methods of their use.
DK1104306T3 (en) Preparations of CpG and Saponin Adjuvants and Methods for Using Them
HK1038507A1 (en) Influenza virus vaccine composition
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
MXPA04001224A (en) Agents for enhancing the immune response.
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
MX349481B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
NO20091665L (en) Tumor-associated antigen derivatives from the MAGE family, and the nucleic acid sequences encoding them, used for the preparation of fusion proteins and for vaccine compositions
NZ525752A (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
MA32821B1 (en) VACCINE COMBINALLY COMBINED AGAINST COQUELUCHE (WHOLE CELLULAR VACCINE)
WO2005021726A3 (en) Immunogenic hiv compositions and related methods
TW200502245A (en) Vaccine
HK1074643A1 (en) Recombinant mva capable of expressing structural hcv antigens